It is therefore tempting to speculate that sustained ERK5 signaling neutralizes the antiproliferative effect of anti-HER2 agents in resistant breast cancer cells by promoting RB phosphorylation through the cyclin E–associated CDK2 complex (Fig. 7D). Here, RB1 is linked to breast cancer.